Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 18 Publications

9 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)		 CDK4/CyclinD1 [1]
(Cell-free assay)		 CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NF\NcJFMcW6jc3WgRZN{[Xl? NVqwT5NUOjRiaB?= NET5O3pKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= MXeyOFY1OTFyMx?=
COLO205 NVvsOmE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDsO|IhcA>? NHHrfZZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>? NIfSXnUzPDZ2MUGwNy=>
U937 M1\EeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7seYRvPzJiaB?= NUTuPGJ7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>? MV:yOFY1OTFyMx?=
MOLM13 M2nuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXaOm84OiCq MlTORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zNNVMh[2WubIOgbIFz[m:{aX7nJGZNXDNiSWTEJI12fGGwdDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODl4IN88US=> MoXZNlQ3PDFzMEO=
MOLM13 NVWzSXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq3NkBp MkHLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDzc5Ji\mWwaXKtdoV{cXO2YX70JIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? MXmyOFY1OTFyMx?=
MDA-MB-435 NGSybmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLGUZAzPCCq M3zRN2lEPTB;MD6xOkDPxE1? M1nzcVE2QDBzOEOx
K562 Ml;QR5l1d3SxeHnjJGF{e2G7 NGX0dVE6PiCq NW\TN4dJTE2VTx?= M{nmcGlEPTB;MjFOwG0> NIDk[HQzPDRzN{W2Oi=>
DU145 MWDDfZRwfG:6aXOgRZN{[Xl? NEOyOG46PiCq M1j4U2ROW09? MVXJR|UxRTdwNTFOwG0> NFrJbY0zPDRzN{W2Oi=>
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLTdXMyKM7:TR?= NG\jUpczPCCq MYTEUXNQ Mn7oR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl Ml[xNlQ1OTd3Nk[=
MCF7 M1jzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jWSlEh|ryP MkDzNlQhcA>? MXnEUXNQ NVrKPFUxS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm MnHrNlQ1OTd3Nk[=
MCF7 MV;LbY5ie2ViQYPzZZk> M1PLW|Uh|ryP MUeyOEBp MljaSG1UVw>? NWjjUWk6UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> M2X5UVI1PDF5NU[2
MDA-MB-231 M2PSW2tqdmG|ZTDBd5NigQ>? NIj3SY82KM7:TR?= NV\1VpVROjRiaB?= M133[WROW09? NFrZ[INKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NVHaPVN[OjR2MUe1OlY>
MDA-MB-231 M2r0NGZ2dmO2aX;uJGF{e2G7 M4rZPVEuOTBizszN NV:1XXF5OjRiaB?= NUL4SZJOTE2VTx?= MmPX[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen MVuyOFQyPzV4Nh?=
MCF7 MVzGeY5kfGmxbjDBd5NigQ>? MVixMVExKM7:TR?= M3rlT|I1KGh? M1npfGROW09? NFfSN|lld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= MVOyOFQyPzV4Nh?=
MDA-MB-231 NHXzNXVHfW6ldHnvckBCe3OjeR?= NXH5fG9oOC53LUGg{txO NWfKRnlPPDhiaB?= MlfaSG1UVw>? MmDDbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> MX:yOFQyPzV4Nh?=
MCF7 MYXGeY5kfGmxbjDBd5NigQ>? NYLPPYlKOC53LUGg{txO MXG0PEBp MnfCSG1UVw>? Mo\mbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> MY[yOFQyPzV4Nh?=
697 NFfTUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPq[HIyUUN3ME2xOFgvOzhibl2= M3XCbHNCVkeHUh?=
P12-ICHIKAWA NXnkVnFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;CTWM2OD17Nj6wOEBvVQ>? MoLoV2FPT0WU
NB69 M3jqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF4MT64JI5O NFLheXhUSU6JRWK=
EoL-1 M4LBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j5NWlEPTB;MUi3MlI3KG6P NHO5RmtUSU6JRWK=
BHT-101 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPIV3FvUUN3ME2xPVgvOjVibl2= MX;TRW5ITVJ?
SK-NEP-1 NFntSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LKT2lEPTB;MkKwMlAzKG6P NVnMNXFvW0GQR1XS
MHH-NB-11 NYW2Ro5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXlTWM2OD1{MkCuNVkhdk1? MX;TRW5ITVJ?
AsPC-1 M4jTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ3Mj61N{BvVQ>? M1ywcHNCVkeHUh?=
ES1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDITGRKSzVyPUK1Ok4zPSCwTR?= NXjaZnNKW0GQR1XS
LAMA-84 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLsWohKSzVyPUK1PE4yQSCwTR?= MmrRV2FPT0WU
MOLT-16 M3HqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrPTFRKSzVyPUK1PE41QSCwTR?= NIXXT3JUSU6JRWK=
ES7 NEn3cnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ5Mz6wPUBvVQ>? MnfZV2FPT0WU
KY821 M32yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3McHNZUUN3ME2zNVQvOSCwTR?= NYLMc5UzW0GQR1XS
RT-112 NHfnbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHzTWM2OD1|MkGuNFUhdk1? NIHWNlFUSU6JRWK=
HL-60 NHXiToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPFTWM2OD1|NECuOlYhdk1? M1S3UnNCVkeHUh?=
MOLT-4 M{S0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP4eYJKSzVyPUO0OU4yOyCwTR?= MUXTRW5ITVJ?
KARPAS-45 NVW5bZRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN5Nj6xOkBvVQ>? NUm3RlltW0GQR1XS
SK-N-AS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPIO4tKSzVyPUO4O{45OyCwTR?= MV7TRW5ITVJ?
CTB-1 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\QbGlEPTB;NEC1MlAzKG6P NVjHd3hxW0GQR1XS
NKM-1 M1r2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTRzMT64PUBvVQ>? M{PNWHNCVkeHUh?=
HTC-C3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Dme2lEPTB;NEOyMlk2KG6P MWfTRW5ITVJ?
BE-13 NUTvbW1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\PUIhKSzVyPUS0OE4zPyCwTR?= MX\TRW5ITVJ?
KOSC-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPWZYRZUUN3ME20OlYvQSCwTR?= NYnt[WFvW0GQR1XS
NB14 NXWzWHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f4SWlEPTB;NEizMlU5KG6P Mn7JV2FPT0WU
CAL-27 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT0N5FKSzVyPUS5OE42QSCwTR?= MX;TRW5ITVJ?
H9 M2nIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW2W5lHUUN3ME20PVUvPDNibl2= MYnTRW5ITVJ?
RS4-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jEZ2lEPTB;NUC0Mlc{KG6P NWnBNHpqW0GQR1XS
PA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzxTWM2OD13MEmuPFYhdk1? NULkS|lbW0GQR1XS
MV-4-11 NWTOOnJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTWS5lWUUN3ME21NVMvQDVibl2= MmT1V2FPT0WU
OS-RC-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jqemlEPTB;NUKxMlYzKG6P NHnKWJFUSU6JRWK=
RPMI-8226 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPocYRKSzVyPUWyOk45PiCwTR?= NIn3TlNUSU6JRWK=
HGC-27 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXHSVFKSzVyPUW2OE46QSCwTR?= MXfTRW5ITVJ?
CHP-212 NH\KcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrvXI9KSzVyPUW5N{42QSCwTR?= NGntW2ZUSU6JRWK=
NB10 M1Xud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LKfWlEPTB;NUm5MlE5KG6P MkXkV2FPT0WU
HH MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ITWM2OD13OUmuOFMhdk1? NGDqZ2hUSU6JRWK=
EW-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13WO2lEPTB;NkCzMlUzKG6P NUHteYZXW0GQR1XS
ES8 M4\wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XSOmlEPTB;NkC1MlIyKG6P MVvTRW5ITVJ?
HAL-01 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTZyNT62O{BvVQ>? Mkn1V2FPT0WU
A204 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTSNGRyUUN3ME22N|MvQTFibl2= MXPTRW5ITVJ?
MHH-PREB-1 M{jidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLRR|hzUUN3ME22N|YvQTlibl2= NXzwdpFDW0GQR1XS
EM-2 NVL3enR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\UbnpOUUN3ME22OVAvPjRibl2= NEf0RoFUSU6JRWK=
BV-173 M1r2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZ3Mj60PEBvVQ>? MnzZV2FPT0WU
ONS-76 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTZ5Nz64NkBvVQ>? NV;JfYFkW0GQR1XS
KM-H2 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTZ7NT61OEBvVQ>? NILiWotUSU6JRWK=
D-263MG NH30[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi5TWtYUUN3ME23NVcvOTJibl2= MW\TRW5ITVJ?
ES3 NGPMRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7JTWM2OD15MkiuPVMhdk1? NGPKZYNUSU6JRWK=
VA-ES-BJ NIq5SWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTvTWM2OD15M{KuNlchdk1? MlP0V2FPT0WU
NBsusSR M2PjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTd2Mj65PUBvVQ>? MYHTRW5ITVJ?
NCI-H520 NIDCd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rQXGlEPTB;N{S2MlUzKG6P MmP1V2FPT0WU
ES5 NYXDfFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XwXWlEPTB;N{WyMlghdk1? MnvZV2FPT0WU
T-24 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPrXohuUUN3ME23O|gvPzFibl2= NYr3cHF5W0GQR1XS
SW962 NXTwW4ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRThyOD62N{BvVQ>? MV7TRW5ITVJ?
EW-3 M2G0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRThyOD63OkBvVQ>? MXLTRW5ITVJ?
RXF393 M{HoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRThzMj63PUBvVQ>? M1f1fXNCVkeHUh?=
U251 NFLkOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRThzMz64PEBvVQ>? MWLTRW5ITVJ?
CAMA-1 NFjaWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X0[WlEPTB;OEOzMlk1KG6P NWjj[YpMW0GQR1XS
JVM-3 M4rCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ezR2lEPTB;OEWxMlc5KG6P NHjlWGJUSU6JRWK=
COLO-800 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zVOGlEPTB;OEm3Mlc5KG6P NUT1fYs4W0GQR1XS
OVCAR-5 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP4VmlKSzVyPUmwNE4yKG6P MljuV2FPT0WU
LB1047-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTl{Nz61OkBvVQ>? M2PYbHNCVkeHUh?=
SW954 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O2b2lEPTB;OUK5MlQyKG6P MXnTRW5ITVJ?
J-RT3-T3-5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknVTWM2OD17M{[uNFYhdk1? MnrLV2FPT0WU
Mewo NULBPFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjybmFKSzVyPUmzOk43KG6P M4POSnNCVkeHUh?=
NCI-H1770 M2DO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S5eWlEPTB;OUSwMlU2KG6P M3S4[3NCVkeHUh?=
HO-1-N-1 M1PycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTl4Mj64NUBvVQ>? MkXCV2FPT0WU
HSC-3 NYXRWWs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jRT2lEPTB;OU[2MlQ5KG6P NH3ybHlUSU6JRWK=
TYK-nu NFzRT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTl7OD6yOUBvVQ>? NVfiXGF2W0GQR1XS
KYSE-150 M{DhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O1XWlEPTB;MT6wNFA4PiEQvF2= NFXxNJNUSU6JRWK=
SN12C MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMEC4O|Uh|ryP NF7I[mtUSU6JRWK=
MOLT-13 NYnIcXF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWwXnFKSzVyPUGuNFE1OjFizszN NILzfHRUSU6JRWK=
TE-11 M33sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\TbItKSzVyPUGuNFQ5OTJizszN NW\Sc5c6W0GQR1XS
DB M4TU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjxNmNmUUN3ME2xMlA4Ojd|IN88US=> MoHCV2FPT0WU
CAL-39 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT0TWM2OD1zLkC3OVIzKM7:TR?= NVPTV5B7W0GQR1XS
A3-KAW NVntN3pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKzTWM2OD1zLkC4OFA5KM7:TR?= NHTQOVJUSU6JRWK=
CHP-134 NVzYRXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjGNVNSUUN3ME2xMlEyQDB5IN88US=> MWnTRW5ITVJ?
TGW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L3XmlEPTB;MT6xNlM6PSEQvF2= NUnQPVdTW0GQR1XS
QIMR-WIL Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\JRmlEPTB;MT6xN|E{PCEQvF2= MU\TRW5ITVJ?
NCI-SNU-1 M{\wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu2TWM2OD1zLkG2N|U1KM7:TR?= MlLhV2FPT0WU
CGTH-W-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwMUexPFYh|ryP MUfTRW5ITVJ?
MHH-ES-1 M4LQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf5XXZEUUN3ME2xMlE4QTh4IN88US=> NI\3d3lUSU6JRWK=
LB2241-RCC NUKxeXRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwMUi2NkDPxE1? NVjrelZzW0GQR1XS
ML-2 NH7BR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTFwMkC3N|Qh|ryP MmLuV2FPT0WU
COR-L23 NIXySFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPSTWM2OD1zLkKyPVM{KM7:TR?= NGLNcXlUSU6JRWK=
BFTC-905 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHToVFlKSzVyPUGuNlQzPjdizszN NUnvUpdpW0GQR1XS
Hs-578-T Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfMT25KSzVyPUGuNlU5OTdizszN NIDvTW1USU6JRWK=
KG-1 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TFVGlEPTB;MT6yOlY5PiEQvF2= MofaV2FPT0WU
HEL Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInjXYtKSzVyPUGuNlk{OzhizszN M4XYRXNCVkeHUh?=
A549 M2TCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jCZWlEPTB;MT6yPVM6QSEQvF2= NFWzNFNUSU6JRWK=
COLO-741 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwM{KwPFkh|ryP NEjacHFUSU6JRWK=
PC-3 M2T2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLRTWM2OD1zLkO1NlIyKM7:TR?= NGWyfIFUSU6JRWK=
HOS NXjWRWhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP3b2hKSzVyPUGuN|UzQTZizszN M1fRO3NCVkeHUh?=
HT-1080 NVPuTnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwM{e1NVkh|ryP NU\OcVh1W0GQR1XS
TE-8 NYn1Zm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwNEG3O|Qh|ryP MWDTRW5ITVJ?
BHY NGfKcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3sblVKSzVyPUGuOFY6OjNizszN MXXTRW5ITVJ?
BB65-RCC M{[x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwNUC1Nlgh|ryP NH7xbHpUSU6JRWK=
HN MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\GTWM2OD1zLkW0NFcyKM7:TR?= M17UdnNCVkeHUh?=
NCI-H441 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwNUS5NFch|ryP M2nq[XNCVkeHUh?=
RPMI-8866 M3HBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH3TWM2OD1zLkW4OVA4KM7:TR?= NGXleIdUSU6JRWK=
CAL-62 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrDTWM2OD1zLk[wPFYzKM7:TR?= NVnHPZZ6W0GQR1XS
MG-63 M1TZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XuOWlEPTB;MT62NVgyOyEQvF2= MWfTRW5ITVJ?
SK-LU-1 NVjPe5MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwNkKxOVIh|ryP M1;1b3NCVkeHUh?=
BCPAP NIXuV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XUNWlEPTB;MT62OlQ2PyEQvF2= NYHUc|hUW0GQR1XS
22RV1 NYLw[mluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjMcoRKSzVyPUGuOlc5PDNizszN NUn5e2R{W0GQR1XS
T47D MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwNkiwOlEh|ryP NEWxZ5NUSU6JRWK=
MSTO-211H Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDETWM2OD1zLk[5OlA{KM7:TR?= NFraeXpUSU6JRWK=
DEL NHe4PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwN{CyO|Mh|ryP MmH3V2FPT0WU
H4 NHfafphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT5TWM2OD1zLkezNlEzKM7:TR?= NF;3NFNUSU6JRWK=
CAL-51 NUi4VWhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknoTWM2OD1zLke0PFU2KM7:TR?= M4\EXnNCVkeHUh?=
ABC-1 NIHIc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwN{i1PFIh|ryP NFvNW3RUSU6JRWK=
MZ2-MEL Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nYUGlEPTB;MT63PVU1OiEQvF2= M4\YVHNCVkeHUh?=
YKG-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j3WWlEPTB;MT64NVA3OSEQvF2= NGK2UY1USU6JRWK=
KM12 M3;rTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;YelduUUN3ME2xMlgyPjB{IN88US=> MkniV2FPT0WU
L-363 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\sd2lEPTB;MT64O|QyOiEQvF2= MlLTV2FPT0WU
KU812 NIfF[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITWTY5KSzVyPUGuPFkzQDJizszN NY\1To9XW0GQR1XS
LOXIMVI MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPXPWh4UUN3ME2xMlkyOjJ6IN88US=> Mn63V2FPT0WU
G-401 NYfuTWhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwOUK0Nlgh|ryP M2Owb3NCVkeHUh?=
SW780 M4S4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDqTWM2OD1zLkm2NlQ3KM7:TR?= NXPDbHl[W0GQR1XS
SW872 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fVW2lEPTB;MT65PFM{KM7:TR?= MlLTV2FPT0WU
NB7 NHTuNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwOUmzNlMh|ryP NHzkPY9USU6JRWK=
T98G MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJwMEC2OlYh|ryP NETh[oxUSU6JRWK=
SW1710 M2C5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKwWJNKSzVyPUKuNFY6PDVizszN NXjNW3J2W0GQR1XS
NCI-H1573 M2PpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVixUVVQUUN3ME2yMlA4Ojl6IN88US=> NVHVdoN2W0GQR1XS
KE-37 NUO5enFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jKSWlEPTB;Mj6wPFk2OSEQvF2= M2TUUnNCVkeHUh?=
786-0 NV;iZoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojOTWM2OD1{LkG1OFM6KM7:TR?= M4ToVnNCVkeHUh?=
SAS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7XUIVKSzVyPUKuNlA{PzRizszN NWfwVIlLW0GQR1XS
CAL-54 M33odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH0S3FYUUN3ME2yMlIxPDF|IN88US=> NYTpRYRHW0GQR1XS
SF268 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LzfGlEPTB;Mj6yN|EzOiEQvF2= MWDTRW5ITVJ?
SW620 M361VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;xSllKSzVyPUKuNlYyPjlizszN NIrycXdUSU6JRWK=
MN-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP6flBKSzVyPUKuN|ExPiEQvF2= MU\TRW5ITVJ?
EFO-27 NIewVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXDZXlNUUN3ME2yMlMzODV6IN88US=> MoPHV2FPT0WU
NCI-H747 M1fGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vyUmlEPTB;Mj6zNlE6QSEQvF2= MoTjV2FPT0WU
HCC2218 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zzNGlEPTB;Mj6zOVM4PCEQvF2= MUjTRW5ITVJ?
MIA-PaCa-2 NHXYNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwM{[0N|ch|ryP M2TC[HNCVkeHUh?=
SJSA-1 NGnTOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJwM{e3PVYh|ryP M1\1cnNCVkeHUh?=
RKO NG\GN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nENWlEPTB;Mj6zPFQ6PiEQvF2= NV\4XIs5W0GQR1XS
NB6 M2Dwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz6TWM2OD1{LkSwN|c1KM7:TR?= NYWyd2NOW0GQR1XS
ES4 MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXMTWM2OD1{LkS1OFIzKM7:TR?= M3XLZXNCVkeHUh?=
EGI-1 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7BRlBKSzVyPUKuOFY5QDNizszN NFTodGJUSU6JRWK=
CTV-1 M3ezOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTZTWM2OD1{LkWyO|c{KM7:TR?= M1HBNHNCVkeHUh?=
NCI-H1355 NX2zWXRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf5SWFKSzVyPUKuOVU6PTFizszN NYXFO|ZKW0GQR1XS
GT3TKB M4DzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO0SJVKSzVyPUKuOVkyQTlizszN NF3NT|ZUSU6JRWK=
SK-HEP-1 M1rjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPGZpBYUUN3ME2yMlU6OjZ4IN88US=> NHzwNYFUSU6JRWK=
GAMG NG\FdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfrbWNKSzVyPUKuOVk{QTRizszN MYrTRW5ITVJ?
SK-MES-1 NXn4fngyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJwNkG4NFMh|ryP NF62WJRUSU6JRWK=
RO82-W-1 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf2UVlKSzVyPUKuOlIxPTdizszN NFvrVYJUSU6JRWK=
ECC10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPtXnJKSzVyPUKuO|AzODZizszN M17SV3NCVkeHUh?=
MCF7 M4LIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn6OW9KSzVyPUKuO|E1PjRizszN Mmq4V2FPT0WU
D-283MED NY\BWIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XSPWlEPTB;Mj63NlQ{KM7:TR?= MWnTRW5ITVJ?
RPMI-7951 NHfRR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwN{W2PVQh|ryP Ml[0V2FPT0WU
Ramos-2G6-4C10 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16xOmlEPTB;Mj63O|A6QSEQvF2= MmL0V2FPT0WU
KGN NV:5Roo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwOEG4PFQh|ryP MXPTRW5ITVJ?
NUGC-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXpTWM2OD1{LkiyOVA2KM7:TR?= MkPCV2FPT0WU
NCI-H292 M4PKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLvbXJHUUN3ME2yMlg2ODV|IN88US=> M2rGXXNCVkeHUh?=
Becker MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLvfpdKSzVyPUKuPVU5OzJizszN NWDTVHUxW0GQR1XS
NCI-H1299 M4DnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLw[lRKSzVyPUOuNFUzPjNizszN NUfJN5o6W0GQR1XS
ETK-1 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjoTWM2OD1|LkC1OFMh|ryP NHfkRoNUSU6JRWK=
TK10 M33mXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNwMkCxOlUh|ryP MYrTRW5ITVJ?
VMRC-RCZ NUXpTWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLIbpJKSzVyPUOuN|Y1QDhizszN NFu0fFBUSU6JRWK=
YH-13 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLpZ2d{UUN3ME2zMlQ1ODd7IN88US=> NFjFVnRUSU6JRWK=
DU-145 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnNcGtSUUN3ME2zMlQ3OjZ7IN88US=> MYjTRW5ITVJ?
SW1088 M4XZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvvTWM2OD1|LkS3OFch|ryP NIi5[nhUSU6JRWK=
HOP-92 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPrWXdKSzVyPUOuOVA{PDJizszN NVz5VVVtW0GQR1XS
KP-N-YS NFvJ[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrsdo4xUUN3ME2zMlYzOTN7IN88US=> NIjxZmZUSU6JRWK=
NCI-H460 NG\jeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWx[VF6UUN3ME2zMlY3PzNizszN Mn3EV2FPT0WU
U-2-OS MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES0XlJKSzVyPUOuO|I2OzVizszN MULTRW5ITVJ?
A101D M1\2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNwN{[5N|Yh|ryP NUTFV2dmW0GQR1XS
MDA-MB-231 NF\KOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV64OFlnUUN3ME2zMlgyQTVzIN88US=> NUPVNlZqW0GQR1XS
IST-MES1 M3H6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X1O2lEPTB;Mz64N|Ih|ryP NVzCUZdsW0GQR1XS
COR-L105 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nvR2lEPTB;ND6wNVgh|ryP NYD0Z3g{W0GQR1XS
NCI-H1437 NXPQZpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTRwMEKzNFIh|ryP M2G1cXNCVkeHUh?=
CAL-85-1 NVf6WWxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwMEK0OlEh|ryP NFjNUJJUSU6JRWK=
MZ1-PC NHXIOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwMUi1OVYh|ryP MYjTRW5ITVJ?
VM-CUB-1 NYfQeFBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1znPGlEPTB;ND6zNVI5PCEQvF2= NG[3RWdUSU6JRWK=
CHL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTRwM{KxOlkh|ryP MnHKV2FPT0WU
MDA-MB-361 NUf4b4VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTRwM{OxOVMh|ryP MWDTRW5ITVJ?
NCI-H661 NIfZUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTRwNUCwPVIh|ryP NXvKXoRTW0GQR1XS
EW-11 NUX0OmpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnYXpZtUUN3ME20MlUzOjNzIN88US=> MYfTRW5ITVJ?
BEN NIL1XFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTQTW5ZUUN3ME20MlUzQDF3IN88US=> M1vZZ3NCVkeHUh?=
BFTC-909 M4nFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkKzTWM2OD12LkW2Nlc2KM7:TR?= MXvTRW5ITVJ?
NCI-H2087 M3TRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTRwNUixOlQh|ryP MWHTRW5ITVJ?
RVH-421 NIjTfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnYbGdKSzVyPUSuOlY3QSEQvF2= NF3VR2lUSU6JRWK=
P30-OHK NXvwZ4xyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvHTWM2OD12Lk[4NFA5KM7:TR?= MYHTRW5ITVJ?
NCI-H28 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRwOEG2OlEh|ryP NHjJUGtUSU6JRWK=
ES6 MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDYTWM2OD12LkizNFE3KM7:TR?= MmHQV2FPT0WU
769-P MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTRwOEW5NlYh|ryP MorKV2FPT0WU
OE33 NYjhW5plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHwV2tKSzVyPUSuPFgyPjFizszN M3jpbXNCVkeHUh?=
SW982 NXfUbVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fKdmlEPTB;ND65OVA3OSEQvF2= MVHTRW5ITVJ?
A388 NF7O[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DOOWlEPTB;NT6wNlk5OyEQvF2= M2m0dHNCVkeHUh?=
TI-73 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDSU2pJUUN3ME21MlA3OTl2IN88US=> NGPIV5RUSU6JRWK=
HCT-116 NXvlcY5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Xi[WlEPTB;NT6wPVg5QSEQvF2= MmHSV2FPT0WU
HuP-T3 NX;wR|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTVwMUi3NFkh|ryP NIfUTnZUSU6JRWK=
G-402 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD3TWM2OD13LkG5OFE3KM7:TR?= NVK5NlBLW0GQR1XS
NCI-H1792 NGfjTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXWTWM2OD13LkK0OlIzKM7:TR?= MkC5V2FPT0WU
NCI-H209 NYnXSXBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELwdYxKSzVyPUWuNlU6PDJizszN M2jYPXNCVkeHUh?=
NCI-H1650 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfIbJZKSzVyPUWuN|A3OzRizszN MUfTRW5ITVJ?
LCLC-97TM1 NHz6V4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;sPXNKSzVyPUWuN|E5ODhizszN NX\TPXk3W0GQR1XS
S-117 NVn3V2xbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTVwM{[5O|Yh|ryP NELoZXdUSU6JRWK=
GI-ME-N MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVwM{m2PFEh|ryP MXzTRW5ITVJ?
NCI-H2122 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTQNJdHUUN3ME21MlQ6Ozl5IN88US=> NEHLfmdUSU6JRWK=
NCI-H1793 Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTVwNke1PVMh|ryP MYPTRW5ITVJ?
C2BBe1 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm2[|hKSzVyPUWuO|AxQDhizszN NV7ySJhDW0GQR1XS
TE-12 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO3TWM2OD13LkiwOVU3KM7:TR?= NH7hXYpUSU6JRWK=
LCLC-103H NY\xfHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf3TWM2OD13LkmxO{DPxE1? M{nld3NCVkeHUh?=
A673 NEXJSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHqPXRKSzVyPUWuPVE6OzJizszN MV;TRW5ITVJ?
BB30-HNC NVr0eWR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHjTWM2OD13Lkm4N|Yh|ryP NVe4TnNLW0GQR1XS
SF295 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrhV2hKSzVyPU[uNFA1OjJizszN NFrrXldUSU6JRWK=
KU-19-19 NETLTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDtTWM2OD14LkCxO|MyKM7:TR?= MoXhV2FPT0WU
CFPAC-1 M3WwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTZwMES0OFMh|ryP MXrTRW5ITVJ?
LoVo MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L2eGlEPTB;Nj6wOVA3OyEQvF2= NHL6[3NUSU6JRWK=
8505C NH[zPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTLUJZ1UUN3ME22MlA4PTd|IN88US=> MXHTRW5ITVJ?
GMS-10 NHjyNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTZwMUWwNFIh|ryP MnuwV2FPT0WU
Ca9-22 MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTZwMU[3NUDPxE1? MVHTRW5ITVJ?
DOK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fmRmlEPTB;Nj6yNlA4OiEQvF2= NFLFTndUSU6JRWK=
FADU NHrxVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwMk[wN|kh|ryP M3yzUXNCVkeHUh?=
BxPC-3 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rJUWlEPTB;Nj6yO|MzKM7:TR?= MnflV2FPT0WU
CAL-33 M3jYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PUfmlEPTB;Nj6yPVIxOSEQvF2= NWDoO4RXW0GQR1XS
SHP-77 M1S2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz6UpI2UUN3ME22MlMyPTF{IN88US=> MnvUV2FPT0WU
LXF-289 M1y3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7RTWM2OD14LkOzOFU2KM7:TR?= NF\Yc|RUSU6JRWK=
GB-1 NWGyRpFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\VdYRKSzVyPU[uN|gzKM7:TR?= NUPVVlA1W0GQR1XS
KS-1 NUD6Znk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7MVGRKSzVyPU[uN|g1PDdizszN NHTqPJFUSU6JRWK=
D-502MG NVrvNnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTZwNEKzO|Yh|ryP NFfEfG1USU6JRWK=
LAN-6 M17CWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHwTWM2OD14LkWxNFI{KM7:TR?= M1LyNnNCVkeHUh?=
H-EMC-SS NXTIcmw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ITWM2OD14LkW2NVQ4KM7:TR?= NVr0coxKW0GQR1XS
LC-2-ad NXjKe5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H1WGlEPTB;Nj62NFA4PiEQvF2= MlzvV2FPT0WU
NCI-H1693 M{TSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnJ[Yo3UUN3ME22MlYzOjF3IN88US=> NG\xb|lUSU6JRWK=
SK-N-FI M1;TOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTZwN{WwOFQh|ryP M4XhPHNCVkeHUh?=
D-423MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjLTWM2OD14Lke2NVE4KM7:TR?= M3zOW3NCVkeHUh?=
KNS-42 M3XmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;5XmxKSzVyPU[uO|gyQTdizszN M2rLUnNCVkeHUh?=
GCT NXjtTYVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D1RmlEPTB;Nj65N|gh|ryP MYLTRW5ITVJ?
DSH1 M3jyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTdwME[zN{DPxE1? MVjTRW5ITVJ?
D-247MG M3r2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLGeIFKSzVyPUeuNFc5QDFizszN MljKV2FPT0WU
NCI-SNU-5 MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXUTWM2OD15LkG4N|cyKM7:TR?= MYrTRW5ITVJ?
TE-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfEb285UUN3ME23MlIxPjBzIN88US=> NEnUWmRUSU6JRWK=
NOMO-1 NWfjXmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTdwMkKxNlch|ryP NVrqcWdXW0GQR1XS
NB17 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jMbGlEPTB;Nz6zNFMxQSEQvF2= M1j0N3NCVkeHUh?=
EW-22 M1jxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYKyNoNDUUN3ME23MlM1OzR6IN88US=> MmLoV2FPT0WU
EW-13 NUjYV5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHkcWtKSzVyPUeuN|UyPjJizszN MknsV2FPT0WU
DOHH-2 NHLIS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTdwNESwNkDPxE1? NF[0dnBUSU6JRWK=
TGBC1TKB MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTEWY13UUN3ME23MlQ6QDl7IN88US=> MUPTRW5ITVJ?
GR-ST NFjZbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7xbI1jUUN3ME23MlUzPTl2IN88US=> NXXodlVVW0GQR1XS
KYSE-520 NIfPRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjDVmNKSzVyPUeuOVU2OTVizszN Ml22V2FPT0WU
CAPAN-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTdwNUm1NUDPxE1? MXjTRW5ITVJ?
HCE-4 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\tXo1KSzVyPUeuOlIzPzlizszN NU\ad5d3W0GQR1XS
MLMA NVOxOol2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTdwNkK5OVch|ryP M3e3TnNCVkeHUh?=
HT-144 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTdwNkWzOlgh|ryP NYHheJJHW0GQR1XS
KYSE-180 NF;CXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\VO|ZnUUN3ME23MlcyOTZ7IN88US=> NF7iOnBUSU6JRWK=
TE-5 M4O4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTdwOUW5O|Eh|ryP NEjwPVVUSU6JRWK=
IGROV-1 M3q5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTdwOUi1OVEh|ryP Mn3oV2FPT0WU
NCI-H1581 NYHsXXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjoTWM2OD16LkCxNkDPxE1? NUTZUGZ3W0GQR1XS
SW1990 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq0OY51UUN3ME24MlA1PjV7IN88US=> MV\TRW5ITVJ?
EFM-19 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnCUodSUUN3ME24MlA5PTR3IN88US=> NWPkdI9RW0GQR1XS
OGR-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRThwNEOwNlMh|ryP M2XLXXNCVkeHUh?=
U-118-MG NESyUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRThwNEO0OlMh|ryP M4\IO3NCVkeHUh?=
SK-OV-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmxTWM2OD16LkS2O|Y2KM7:TR?= MYTTRW5ITVJ?
KNS-62 NWLi[JF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvufIlKSzVyPUiuOVE4PjFizszN Mke1V2FPT0WU
GOTO M1rEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L3fmlEPTB;OD61O|Y{PSEQvF2= MX7TRW5ITVJ?
8305C MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHIVoVKSzVyPUiuO|A1QDRizszN MlnvV2FPT0WU
RPMI-2650 NFXZcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkntTWM2OD16LkexPVU2KM7:TR?= MXfTRW5ITVJ?
NEC8 M4XHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X3VWlEPTB;OD63OFMxPyEQvF2= M1rGR3NCVkeHUh?=
KYSE-450 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\QTWM2OD16Lki2OVQ5KM7:TR?= MXHTRW5ITVJ?
RMG-I NEXzbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle4TWM2OD17LkG0NFU5KM7:TR?= M2DlZnNCVkeHUh?=
CAKI-1 NHO0elVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[2fpJKSzVyPUmuN|E6PzlizszN M3jseXNCVkeHUh?=
KYSE-510 NIfPTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j1SGlEPTB;OT6zOVc4QCEQvF2= MYTTRW5ITVJ?
A4-Fuk NWPxXIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DBPWlEPTB;OT6zOlcxOSEQvF2= MUDTRW5ITVJ?
AN3-CA Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXeyWHE5UUN3ME25MlQ2PDR2IN88US=> NWHkd45[W0GQR1XS
SK-N-DZ NYXRdHlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TPTmlEPTB;OT63Nlg1QSEQvF2= M{TLNHNCVkeHUh?=
HSC-2 M4q1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP3UYhKSzVyPUmuO|Y3OjlizszN MVXTRW5ITVJ?
EW-1 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fxcWlEPTB;OT63PVM3QSEQvF2= NGm2NINUSU6JRWK=
D-566MG NELtTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTSWIxKSzVyPUmuPFM3PjRizszN M3jiTnNCVkeHUh?=
COLO-792 NHL2OGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTlwOUi3OFYh|ryP NHfMdpJUSU6JRWK=
TE-10 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XVdWlEPTB;MUCuNFM6PiEQvF2= M2\mW3NCVkeHUh?=
NCI-H650 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjaU3RKSzVyPUGwMlQzQDZizszN MVnTRW5ITVJ?
U-266 NHLkTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3KTWM2OD1zMD60OVUh|ryP MXnTRW5ITVJ?
Detroit562 NH\KN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfKTWM2OD1zMT6wOVE2KM7:TR?= NInwbHZUSU6JRWK=
NH-12 NWfLdmJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\LSFJxUUN3ME2xNU4yPDR4IN88US=> NXXIR2dEW0GQR1XS
CO-314 M1riUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmyTWM2OD1zMT6yPFQzKM7:TR?= MkGxV2FPT0WU
IST-MEL1 M{C3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDQSZpyUUN3ME2xNU42OzJ|IN88US=> MWfTRW5ITVJ?
KNS-81-FD MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLuTWM2OD1zMT61OVI4KM7:TR?= NV[xc|hSW0GQR1XS
SW1463 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFzLkW5PFkh|ryP NEezeFZUSU6JRWK=
NCI-H23 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnURXU3UUN3ME2xNU43PTV{IN88US=> NVuxeVFQW0GQR1XS
SK-MEL-2 NHLWVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzrN2hKSzVyPUGxMlcyQTdizszN NXfEbno6W0GQR1XS
NB13 NECwSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XjZWlEPTB;MUKuNVQ6PSEQvF2= M1TjeHNCVkeHUh?=
Daoy MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\RV|NKSzVyPUGyMlI5PTZizszN NVG1XIpuW0GQR1XS
NCI-H1623 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF{LkO4NFEh|ryP MUjTRW5ITVJ?
NMC-G1 NGDHcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3RTWM2OD1zMj63NVch|ryP MnjtV2FPT0WU
DK-MG M3LQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF{Lkm0PFIh|ryP NFz2W4FUSU6JRWK=
TCCSUP NI\ITmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXKfGdTUUN3ME2xN{4yOjh2IN88US=> MV\TRW5ITVJ?
SCC-15 NHLmfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF|LkK2OVEh|ryP MlHGV2FPT0WU
NOS-1 M17Gd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnpTWM2OD1zMz6yPFk{KM7:TR?= NUH2d5NtW0GQR1XS
RH-1 M4fvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF|LkOwN|ch|ryP NEHLZZBUSU6JRWK=
SK-MEL-3 M1jQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXoTWM2OD1zMz6zO|I5KM7:TR?= MWnTRW5ITVJ?
NB5 NVXXTJd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF|LkSwOlch|ryP M3fWXXNCVkeHUh?=
SNU-387 M4TS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLhPZdKSzVyPUGzMlUxPzJizszN M4XLWHNCVkeHUh?=
CAL-120 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLyRotKSzVyPUGzMlY4OThizszN NH[yWoJUSU6JRWK=
Mo-T M{LQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvZTWM2OD1zMz63NFch|ryP NHfZbHRUSU6JRWK=
LNCaP-Clone-FGC NEf6SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPxTWM2OD1zMz63PVkzKM7:TR?= NGPvV25USU6JRWK=
CAN M37kOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H3SmlEPTB;MUSuNFI5QCEQvF2= M3vKfHNCVkeHUh?=
SK-MEL-30 NY\iSYNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O0PGlEPTB;MUSuNFY{KM7:TR?= MnuxV2FPT0WU
COLO-678 NXzWb5IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF2LkC4NlIh|ryP M3i3PHNCVkeHUh?=
SCC-9 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF32ZopKSzVyPUG0MlExOjFizszN MULTRW5ITVJ?
KINGS-1 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF2LkG0NFIh|ryP MUPTRW5ITVJ?
SL-513 NFzPTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSyTWM2OD1zND6xPFch|ryP NHn6TW5USU6JRWK=
HLE MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;4TWM2OD1zND6zPFUzKM7:TR?= M1vXU3NCVkeHUh?=
SW1573 NWT0Vml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDiXXJKSzVyPUG0MlQ1OzVizszN M3uxT3NCVkeHUh?=
KYSE-140 NX33RZk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfPTWM2OD1zND62N|I4KM7:TR?= NXT5fHNrW0GQR1XS
SK-PN-DW MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jo[2lEPTB;MUSuPFAxOSEQvF2= MYrTRW5ITVJ?
A253 NYPVWpQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF3LkC2NlUh|ryP NYHvfYFEW0GQR1XS
CAL-12T MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF3LkS2OlIh|ryP M3vSUnNCVkeHUh?=
COLO-679 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHFXZVzUUN3ME2xOU44Pjh|IN88US=> Mke3V2FPT0WU
UACC-257 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;nWoplUUN3ME2xOk4yOjBzIN88US=> MoO4V2FPT0WU
U-87-MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrDRm9KSzVyPUG2MlM2OjNizszN NE\UTYdUSU6JRWK=
HCC1806 M{C4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF4LkewO|Eh|ryP MYjTRW5ITVJ?
NCI-H2170 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nkOmlEPTB;MUeuNlQ1QCEQvF2= MYDTRW5ITVJ?
AGS Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHWfItKUUN3ME2xO{4{QDB6IN88US=> MX3TRW5ITVJ?
MEL-HO NEjnTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjlTWM2OD1zNz63OVA{KM7:TR?= MlLRV2FPT0WU
SW48 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3iyTGlEPTB;MUeuO|cyPiEQvF2= NVjlNINvW0GQR1XS
HuP-T4 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uzNWlEPTB;MUiuNFIxPiEQvF2= MYXTRW5ITVJ?
NCI-H720 MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF6LkG0NFIh|ryP MonzV2FPT0WU
RCC10RGB Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXIW5lKSzVyPUG4MlE3QTdizszN M3noPHNCVkeHUh?=
HD-MY-Z MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPXSY9KSzVyPUG4MlIzPTRizszN NHrLcWpUSU6JRWK=
A427 M1faOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz5VZRKSzVyPUG4MlUxQTRizszN M4fSWXNCVkeHUh?=
HCC2998 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF6Lk[wOVEh|ryP Ml7wV2FPT0WU
EPLC-272H NWmxbod6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[3e4hKSzVyPUG5MlA1OzRizszN NHjOUW9USU6JRWK=
C32 M1PVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LvUWlEPTB;MUmuNFQ2KM7:TR?= NH:5UIVUSU6JRWK=
UMC-11 NW\TcHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni5TWM2OD1zOT6yNVI{KM7:TR?= M3GzU3NCVkeHUh?=
CaR-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;JZ|dKSzVyPUG5MlY5ODRizszN NWTjOW9FW0GQR1XS
KYSE-410 M{DPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF7LkmxN|kh|ryP Ml75V2FPT0WU
HuCCT1 NUPuV|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJyLk[yPVQh|ryP MV;TRW5ITVJ?
LB996-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJyLkexOlgh|ryP NHLuOHdUSU6JRWK=
KYSE-70 M3G4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\lTWM2OD1{MD64NFU6KM7:TR?= M{LrXHNCVkeHUh?=
CAL-72 NVfpTlY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJyLkmxOUDPxE1? MYfTRW5ITVJ?
Capan-2 NIHtXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJzLkC0NVMh|ryP Ml36V2FPT0WU
PANC-08-13 NHHWb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLmWFFKSzVyPUKxMlI2OTVizszN M{D4THNCVkeHUh?=
SBC-1 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJzLkOwPFEh|ryP MWDTRW5ITVJ?
MFM-223 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37MN2lEPTB;MkGuN|M1OiEQvF2= Mlj5V2FPT0WU
BB49-HNC NH7KdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJzLkW3NVYh|ryP NX;QNnNnW0GQR1XS
SH-4 NHm0So5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jZdmlEPTB;MkGuOlYyQCEQvF2= M3rqeXNCVkeHUh?=
HuO9 M1LkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki5TWM2OD1{MT65PFI2KM7:TR?= M1;yO3NCVkeHUh?=
AM-38 M2LxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ{LkC0PFUh|ryP M2DpdHNCVkeHUh?=
A431 NGPPeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ|LkKxNVkh|ryP NF;wXnhUSU6JRWK=
YAPC MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ|LkK2OVEh|ryP M2\DcnNCVkeHUh?=
LU-139 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnyUJd2UUN3ME2yN{41QDB7IN88US=> Mn7ZV2FPT0WU
HEC-1 M{Tsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPyTWM2OD1{Mz60PVM4KM7:TR?= NWDH[ZJMW0GQR1XS
SCC-25 NG\JdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTiTWM2OD1{ND6zNFA3KM7:TR?= MmPFV2FPT0WU
HT-29 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ2LkO4NlMh|ryP NWrWPFJLW0GQR1XS
PC-14 NUP1SnNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP5UJlyUUN3ME2yOE43PTdzIN88US=> NEDuS49USU6JRWK=
Calu-6 NFPzXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7WTWM2OD1{NT61NFcyKM7:TR?= MUfTRW5ITVJ?
SJRH30 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHlTWM2OD1{NT62OFk3KM7:TR?= M{Ox[3NCVkeHUh?=
ChaGo-K-1 NH\1WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCwTWM2OD1{Nj6xOlI6KM7:TR?= MUHTRW5ITVJ?
IA-LM NHric3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vTSmlEPTB;Mk[uN|Y1PSEQvF2= MYfTRW5ITVJ?
GP5d NVjtT3RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\1WpJKSzVyPUK2MlQ1QTFizszN NHvUTW5USU6JRWK=
NCI-H2291 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\HcGlEPTB;Mk[uOlU1OSEQvF2= M2rOUXNCVkeHUh?=
BALL-1 NILhd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXMRWtmUUN3ME2yOk46Ozl5IN88US=> NYn3b5hQW0GQR1XS
HCC1954 NUT2NpVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\rTWM2OD1{Nj65PFA5KM7:TR?= M4HDO3NCVkeHUh?=
NCI-H2452 M3LKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrxSWFmUUN3ME2yO{41OTZ|IN88US=> NXvWWHV[W0GQR1XS
LU-99A NI\3d4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjZTWM2OD1{Nz61OVgzKM7:TR?= NEnINWFUSU6JRWK=
NTERA-S-cl-D1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH0S45KSzVyPUK3MlczQTlizszN MmDpV2FPT0WU
PANC-10-05 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ5Lke3O|Uh|ryP M1PXOHNCVkeHUh?=
NCI-H2405 M2\Nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrKdHRKSzVyPUK3Mlk{QDdizszN NFXDS3lUSU6JRWK=
MDA-MB-415 NEXPdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrScWxrUUN3ME2yPE41OTN5IN88US=> MX7TRW5ITVJ?
NCI-H2342 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y4UmlEPTB;MkiuOVI5OSEQvF2= MYnTRW5ITVJ?
TGBC24TKB M1rs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\wTXFqUUN3ME2yPE44OTF5IN88US=> MX\TRW5ITVJ?
LU-134-A MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPiZlY5UUN3ME2yPE46OjZzIN88US=> M4nTVXNCVkeHUh?=
SCC-4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP1[oRYUUN3ME2zNU4xPDl2IN88US=> NXHV[5RPW0GQR1XS
Saos-2 NFP5eFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfqR3hqUUN3ME2zNU46OzB4IN88US=> NEPOfGJUSU6JRWK=
RERF-LC-MS NHnKR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f6eWlEPTB;M{KuPFI{OSEQvF2= MkTjV2FPT0WU
M14 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN{Lkm3OlQh|ryP NXLrPINmW0GQR1XS
HPAF-II NGHMWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7KW4xKSzVyPUOzMlUxOTFizszN MV;TRW5ITVJ?
NCI-H1755 Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN2LkOzNFUh|ryP MXXTRW5ITVJ?
D-392MG NGW4RZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XF[mlEPTB;M{WuPFY4PCEQvF2= MnHUV2FPT0WU
A704 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjXNIxKSzVyPUO2MlA1OjdizszN MYTTRW5ITVJ?
CP50-MEL-B MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDOdoFKSzVyPUO2MlE6OTFizszN NHeyV3BUSU6JRWK=
EW-18 M3LHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G3OWlEPTB;M{[uOFUzKM7:TR?= NE\zOVBUSU6JRWK=
WM-115 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\KSZU{UUN3ME2zOk45ODl7IN88US=> NGLFbolUSU6JRWK=
LU-65 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXQTWM2OD1|Nz6xOFE4KM7:TR?= NWezVZJyW0GQR1XS
NCI-H1563 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN5LkK0PFQh|ryP NVXDPJlHW0GQR1XS
DBTRG-05MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG1TWM2OD1|OD6wOlkyKM7:TR?= Mo\BV2FPT0WU
NCI-H630 NYTremV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G2XWlEPTB;M{iuOFcyPCEQvF2= MlvpV2FPT0WU
NCI-H1155 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN7LkK0NkDPxE1? MkXqV2FPT0WU
OVACR-3 M4HyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPsTWM2OD1|OT65NVk2KM7:TR?= Mmj6V2FPT0WU
OAW-42 M3HH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrrdFRZUUN3ME20NE41OjV6IN88US=> NG\1OnNUSU6JRWK=
JVM-2 NVnrU|B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT6TWM2OD12MT6yOFE2KM7:TR?= MX;TRW5ITVJ?
C3A M{f0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTRzLkO0OFch|ryP NXfyZVZ4W0GQR1XS
HT55 M2G1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPjSWZKSzVyPUSyMlI5PDFizszN MlnWV2FPT0WU
OVCAR-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH5dXZKSzVyPUSyMlI6PzRizszN MVLTRW5ITVJ?
MEG-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDVW|dXUUN3ME20Nk41PjF4IN88US=> MYjTRW5ITVJ?
NCI-H82 NGXRUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPHc5RKSzVyPUSzMlk5QTJizszN MljkV2FPT0WU
JEG-3 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWzT5JyUUN3ME20OE46PDdizszN Mof6V2FPT0WU
BPH-1 NIfoR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2zbHJKSzVyPUS2MlM6QThizszN NX;MU5F{W0GQR1XS
MPP-89 M4[2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPxS29KSzVyPUS3MlI5QThizszN NV65NGNLW0GQR1XS
ALL-PO MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3peY9KSzVyPUS3MlQyQDhizszN M4XQXHNCVkeHUh?=
HT M1G3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zBdWlEPTB;NEeuOFkzKM7:TR?= NHT6R2dUSU6JRWK=
NCI-H2347 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f1N2lEPTB;NEiuNFcyPSEQvF2= NWLEfo44W0GQR1XS
A2780 NHrBeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDTTWM2OD12OT60NlI5KM7:TR?= MnXkV2FPT0WU
KARPAS-299 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTR7LkWxNVkh|ryP M2P2enNCVkeHUh?=
NCI-H1651 NF7M[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPrPFhKSzVyPUS5Mlg5OjFizszN NEjqRnRUSU6JRWK=

... Click to View More Cell Line Experimental Data
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]
+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]
+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing. 		6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl
CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03472573 Recruiting Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University May 9 2018 Phase 1
NCT03423199 Recruiting Breast Neoplasms National Cancer Center Japan|Pfizer|Korean Cancer Study Group February 9 2018 Phase 3
NCT03147287 Recruiting Metastatic Breast Cancer Dana-Farber Cancer Institute|Pfizer August 9 2017 Phase 2
NCT02905318 Recruiting Prostate Cancer Canadian Cancer Trials Group|Pfizer February 9 2017 Phase 2
NCT03535506 Recruiting DCIS Georgetown University|Pfizer October 8 2018 Phase 2
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer January 7 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

  • Pan CDK Inhibitor

    BAY 1000394 : Pan-CDK1/2/3/4/7/9 inhibitor, IC50=5-25 nM.

  • Most Potent CDK Inhibitor

    LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

  • SU9516 New

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A New

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib mesylate (LY2835219)

    abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID